Barclays PLC Buys Shares of 16,400 MBX Biosciences, Inc. (NYSE:MBX)

Barclays PLC purchased a new position in MBX Biosciences, Inc. (NYSE:MBX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,400 shares of the company’s stock, valued at approximately $426,000.

Other large investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in MBX Biosciences in the 3rd quarter valued at $278,000. Point72 Asset Management L.P. acquired a new stake in shares of MBX Biosciences in the third quarter valued at about $405,000. Point72 DIFC Ltd purchased a new position in shares of MBX Biosciences in the third quarter worth about $624,000. Jane Street Group LLC purchased a new position in shares of MBX Biosciences in the third quarter worth about $690,000. Finally, Soros Fund Management LLC acquired a new position in MBX Biosciences during the third quarter worth about $779,000.

MBX Biosciences Price Performance

Shares of NYSE MBX opened at $18.59 on Friday. The business’s 50 day moving average price is $20.30. MBX Biosciences, Inc. has a 1 year low of $15.31 and a 1 year high of $27.50.

MBX Biosciences (NYSE:MBX) last posted its earnings results on Thursday, November 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.72) by ($0.06). On average, sell-side analysts expect that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on MBX shares. Jefferies Financial Group began coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They issued a “buy” rating and a $35.00 price objective for the company. Guggenheim began coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $44.00 price objective on the stock. Stifel Nicolaus began coverage on MBX Biosciences in a research note on Tuesday, October 8th. They set a “buy” rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. started coverage on MBX Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $30.00 target price for the company.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.